Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
08:32am, Wednesday, 03'rd Jun 2026
Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITU
Dow, S&P 500 Hit Fresh Records After Market Rebound
11:53am, Tuesday, 02'nd Jun 2026
Stocks are higher midday, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJI) hitting record highs
Legend's experimental cell therapy shows promise in blood cancer patients
09:31am, Tuesday, 02'nd Jun 2026
Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer, the company said on Tuesday.
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising prelimin
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
10:00am, Monday, 01'st Jun 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinic
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
07:14am, Monday, 01'st Jun 2026
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
10:03pm, Sunday, 31'st May 2026
Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multi
Legend Biotech Announces Presentations at ASCO 2026
05:00pm, Thursday, 21'st May 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at t
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
03:36pm, Sunday, 17'th May 2026
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
02:07pm, Wednesday, 13'th May 2026
Legend Biotech Corp (NASDAQ:LEGN) reported downbeat results for the first quarter on Tuesday.
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
01:30pm, Tuesday, 12'th May 2026
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Q1 Earnings Call Highlights
09:07am, Tuesday, 12'th May 2026
Legend Biotech NASDAQ: LEGN reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of tre
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
07:00am, Tuesday, 12'th May 2026
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets, followin
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
08:00am, Monday, 04'th May 2026
SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguish
